Kerry S. Campbell

Kerry Campbell is a leading NK cell biologist who has made foundational contributions to understanding ADCC (antibody-dependent cellular cytotoxicity) mediated by NK cells via the CD16a (FcgRIIIA) receptor. His research has defined the molecular mechanisms by which NK cells recognize antibody-coated tumor cells and trigger cytotoxic responses. He has characterized polymorphisms in CD16a that influence ADCC efficiency and clinical responses to therapeutic monoclonal antibodies. His work provides the mechanistic basis for strategies to enhance antibody-NK cell synergy in cancer immunotherapy.